Abstract：Objective To investigate the clinical effect of Amisulpride and Risperidone in male schizophrenia patients.Methods A total of 84 male schizophrenia patients admitted to our hospital from January 2018 to March 2019 were selected as subjects, and divided into the control group (42 cases) and the study group (42 cases) according to the blinded method. The control group was treated with Risperidone, while the study group was treated with Amisulpride. The symptom scores, total effective rate, adverse event rate, emotional situation and quality of life were compared. Results There were no statistically significant differences between the positive syndrome scale score, negative syndrome scale score, psychopathological scale score, positive and negative syndrome scale (PANSS) total score of the two groups before treatment (P＞0.05). The positive syndrome scale score, negative syndrome scale score, psychopathological scale score, and PANSS total score of the two groups after treatment were lower than those before treatment, and the differences were statistically significant (P＜0.05). The positive syndrome scale score, negative syndrome scale score, psychopathological scale score, and PANSS total score of the study group after treatment were lower than those in the control group, and the differences were statistically significant (P ＜0.05). The total effective rate in the study group(92.86%) was higher than that in the control group (78.57%), and the difference was statistically significant (P＜0.05).The overall incidence rate of adverse reactions in the study group (9.52%) was lower than that in the control group(23.81%), and the difference was statistically significant (P＜0.05). There were no statistically significant differences between the self-rating anxiety scale (SAS) and the selfrating depression scale (SDS) of the two groups before treatment (P＞0.05). The SAS and SDS scores of the two groups after treatment were lower than those before treatment,and the differences were statistically significant (P＜0.05). The SAS and SDS scores of the study group after treatment were lower than those in the control group, and the differences were statistically significant (P＜0.05). There was no statistically significant difference of the quality of life score between the two groups before treatment (P＞0.05). The quality of life scores of the two groups after treatment were higher than those before treatment, and the differences were statistically significant (P＜0.05). The quality of life scores of the study group after treatment was higher than that in the control group, and the difference was statistically significant (P＜0.05). Conclusion Amisulpride can improve the therapeutic effect and the quality of life, effectively control the disease, relieve the disease symptoms, reduce the incidence rate of adverse reactions and promote the fast recovery.
常凤坤;洪二郎;李桂兰;李德生;高海龙. 氨磺必利与利培酮治疗男性精神分裂症的临床效果比较[J]. 中国当代医药, 2020, 27(25): 74-77.
CHANG Feng-kun ;HONG Er-lang; LI Gui-lan; LI De-sheng ;GAO Hai-long. Clinical effect comparison of Amisulpride and Risperidone in the treatment of male schizophrenia patients. 中国当代医药, 2020, 27(25): 74-77.
京公网安备 11010502046607号